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The Comprehensive Geriatric Assessment in Oncology is now
usually considered the instrument to evaluate elderly cancer
patients, but there is no clear model for practical use of geriatric
instruments. We are working to obtain a useful prognostic-thera-
peutic index ease to use in clinical practice.
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Background: The estimated incidence rates for all cancers in
European men and women is 2.9  100,000 in the 70 years or more
group and 2.2  100,000 in the 55–64 age group. Given the great
importance of elderly population in cancer, it is interesting to
assess their management with modern chemotherapeutic regi-
mens considering tollerability and toxicity. Because elderly
patients are frequently excluded from randomized trials, data
regarding toxicity and tollerabilty are lacking.
Aims: To assess incidence of toxicity complications in this set-
ting of patients.
Patients and methods: From October 2004 to March 2008 a total
of 30 cancer (12 left colon, 6 right colon, 6 rectal and 6 gastric)
patients older than 70 years, treated with Folfox regimen, were
evaluated for chemotherapy-related toxicity. Median age was 71
(range 70–80), 24 (80%) were treated with Folfox4 regimen and 6
(20%) with Folfox6. 26 (87%) patients were stage IV colon and gas-
tric cancer and 4 (12%) were stage III colon cancer. In stage IV can-
cer, 22 (73%) patient underwent Folfox regimen as first line
chemotherapy, 3 as second line and 1 as third line. Toxicity was
evaluated according by NCI-CTC version 2.0.
Results: A total of 146 cycles were administered; 16 (54%)
patients completed 6 cycles of Folfox, 14 (46%) stopped Folfox
administration for PD. The most common comorbidity was hyper-
tensions (17 patients 57%), 5 (16.6%) had no comorbidities. Grades
3 and 4 toxicity occurred in 73% of patients. The main toxicities
was neutropenia, observed in 64% of patients (afebrile grade 4
in 3 (10%) patients, grade 3 in 6 (20%) patients); sensory neurotox-
icity occurred in 70% patients (6 (20%) grade 3 and 15 (50%)
grade 2). Grade 3 diarrhoea occurred in 4 (13.3%) patients, 15
(50%) had grade 2 diarrhoea. 3 (10%) patients had grade 3 mucosi-
tis and 11 (36.6%) had grade 2. Two patients developed atrial flut-
ter but hearth rate and sinus rhythm were restored with
medication. No grade 4 neurotoxicity, diarrhoea and mucositis
was observed.
Conclusion: In our results therapeutic compliance of patients
aged >70 was good. Elderly patients experienced only slightly
more toxicity than younger patients in the two most common
side effects of Folfox: neutropenia and sensory neuropathy.
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